Folgen
Frederik Persson
Frederik Persson
Steno Diabetes Center Copenhagen
Bestätigte E-Mail-Adresse bei regionh.dk
Titel
Zitiert von
Zitiert von
Jahr
Aliskiren combined with losartan in type 2 diabetes and nephropathy
HH Parving, F Persson, JB Lewis, EJ Lewis, NK Hollenberg
New England Journal of Medicine 358 (23), 2433-2446, 2008
15342008
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ...
New England Journal of Medicine 367 (23), 2204-2213, 2012
14502012
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs …
KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ...
The lancet Diabetes & endocrinology 5 (9), 709-717, 2017
3392017
Urinary proteomics for early diagnosis in diabetic nephropathy
P Zürbig, G Jerums, P Hovind, RJ MacIsaac, H Mischak, SE Nielsen, ...
Diabetes 61 (12), 3304-3313, 2012
2772012
Diagnosis of diabetic kidney disease: state of the art and future perspective
F Persson, P Rossing
Kidney international supplements 8 (1), 2-7, 2018
2302018
Diagnosis and prediction of CKD progression by assessment of urinary peptides
JP Schanstra, P Zürbig, A Alkhalaf, A Argiles, SJL Bakker, J Beige, ...
Journal of the American Society of Nephrology 26 (8), 1999-2010, 2015
2152015
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl …
F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ...
Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018
1952018
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
F Persson, P Rossing, KJ Schjoedt, T Juhl, L Tarnow, CDA Stehouwer, ...
Kidney international 73 (12), 1419-1425, 2008
1832008
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria
F Persson, P Rossing, H Reinhard, T Juhl, CDA Stehouwer, C Schalkwijk, ...
Diabetes care 32 (10), 1873-1879, 2009
1812009
Implementation of proteomic biomarkers: making it work
H Mischak, JPA Ioannidis, A Argiles, TK Attwood, E Bongcam‐Rudloff, ...
European journal of clinical investigation 42 (9), 1027-1036, 2012
1622012
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria
CN Rathcke, F Persson, L Tarnow, P Rossing, H Vestergaard
Diabetes care 32 (2), 323-328, 2009
1592009
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus
SS Roscioni, D De Zeeuw, ME Hellemons, H Mischak, P Zürbig, ...
Diabetologia 56, 259-267, 2013
1542013
Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function
S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink
Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017
1352017
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational …
N Tofte, M Lindhardt, K Adamova, SJL Bakker, J Beige, JWJ Beulens, ...
The lancet Diabetes & endocrinology 8 (4), 301-312, 2020
1292020
Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY …
M Lindhardt, F Persson, G Currie, C Pontillo, J Beige, C Delles, ...
BMJ open 6 (3), e010310, 2016
1252016
Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy
J Siwy, JP Schanstra, A Argiles, SJL Bakker, J Beige, P Boucek, K Brand, ...
Nephrology Dialysis Transplantation 29 (8), 1563-1570, 2014
1222014
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy
F Persson, P Rossing, P Hovind, CDA Stehouwer, C Schalkwijk, L Tarnow, ...
Diabetes 55 (12), 3550-3555, 2006
1212006
Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes
S Theilade, M Lajer, F Persson, C Joergensen, P Rossing
Diabetes care 36 (3), 715-721, 2013
1162013
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
F Persson, P Rossing, P Hovind, CDA Stehouwer, CG Schalkwijk, ...
Scandinavian journal of clinical and laboratory investigation 68 (8), 731-738, 2008
1072008
Microalbuminuria: a parameter that has changed diabetes care
HH Parving, F Persson, P Rossing
Diabetes research and clinical practice 107 (1), 1-8, 2015
1022015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20